Vertex said that the drug, VX-770, which is designed to counter one specific genetic mutation, improved lung function in people with cystic fibrosis in a late-stage clinical trial.
Click here to read more.
Vertex said that the drug, VX-770, which is designed to counter one specific genetic mutation, improved lung function in people with cystic fibrosis in a late-stage clinical trial.
Click here to read more.